Details of the Drug
General Information of Drug (ID: DMZTDCL)
Drug Name |
3-Bromo-5-phenylsalicylc acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4906-68-7; CHEMBL387536; 3-bromo-5-phenylsalicylic acid; 3-bromo-5-phenylsalicyclic acid; 5-bromo-4-hydroxybiphenyl-3-carboxylic acid; 5-Bromo-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3-bromo-2-hydroxy-5-phenylbenzoic acid; 3-Bromo-5-phenylsalicylc acid; NSC109116; [1,1'-biphenyl]-3-carboxylic acid, 5-bromo-4-hydroxy-; AC1L6KWF; AC1Q25S5; SCHEMBL18319714; KS-00002WWQ; CTK1D8664; 3-bromo-5-phenyl-Salicylic Acid; DTXSID70296397; MolPort-018-496-593; XVZSXNULHSIRCQ-UHFFFAOYSA-N; ZINC1701218; BDBM50219490; AKOS005151372
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 293.11 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||